KRS Capital Management LLC bought a new stake in Stryker Co. (NYSE:SYK – Get Rating) during the 4th quarter, HoldingsChannel reports. The fund bought 278 shares of the medical technology company’s stock, valued at approximately $74,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Greenleaf Trust boosted its holdings in shares of Stryker by 0.9% in the 3rd quarter. Greenleaf Trust now owns 20,423,471 shares of the medical technology company’s stock valued at $5,386,078,000 after buying an additional 184,760 shares in the last quarter. Wellington Management Group LLP raised its position in Stryker by 43.8% during the 3rd quarter. Wellington Management Group LLP now owns 12,408,440 shares of the medical technology company’s stock worth $3,272,353,000 after buying an additional 3,780,982 shares during the last quarter. Capital Research Global Investors raised its position in Stryker by 4.4% during the 3rd quarter. Capital Research Global Investors now owns 9,760,229 shares of the medical technology company’s stock worth $2,573,990,000 after buying an additional 415,448 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Stryker by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 5,227,951 shares of the medical technology company’s stock valued at $1,393,901,000 after purchasing an additional 107,400 shares in the last quarter. Finally, Morgan Stanley increased its holdings in shares of Stryker by 9.1% during the 3rd quarter. Morgan Stanley now owns 3,422,874 shares of the medical technology company’s stock valued at $902,679,000 after purchasing an additional 285,571 shares in the last quarter. 74.52% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts have issued reports on SYK shares. Piper Sandler lowered their target price on shares of Stryker from $315.00 to $290.00 in a research note on Friday, April 29th. Evercore ISI reiterated an “outperform” rating and set a $284.00 price target on shares of Stryker in a research note on Tuesday, March 15th. BTIG Research boosted their price objective on Stryker from $273.00 to $278.00 in a research report on Monday, April 18th. Bank of America started coverage on Stryker in a research report on Tuesday, March 1st. They set a “buy” rating for the company. Finally, Citigroup lowered their price target on Stryker from $310.00 to $280.00 in a report on Tuesday, May 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $290.89.
Stryker (NYSE:SYK – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The medical technology company reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.04. The business had revenue of $4.30 billion for the quarter, compared to analyst estimates of $4.19 billion. Stryker had a return on equity of 24.09% and a net margin of 11.56%. The company’s revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.93 EPS. Sell-side analysts expect that Stryker Co. will post 9.64 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Thursday, June 30th will be given a dividend of $0.695 per share. This represents a $2.78 annualized dividend and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, June 29th. Stryker’s dividend payout ratio (DPR) is presently 52.85%.
Stryker Profile (Get Rating)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.
- Get a free copy of the StockNews.com research report on Stryker (SYK)
- Under Armor Stock is Getting Undervalued
- Time to Ring the Register on Funko Stock
- Oracle Corporation: A Falling Knife
- Yandex N.V: Pressure Under Sanctions and Semiconductor Shortages
- MarketBeat: Week in Review 5/16 – 5/20
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.